BioPharmSignal logoBioPharmSignal

Biotech News

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Prelude Therapeutics (PRLD)Prelude TherapeuticsFDA / regulatory

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026. WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S.

Related news

PRLDPrelude Therapeutics2026-10-13 11:01 EST

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

LEGNLegend Biotech Corporation2026-10-15 12:00 EST

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

URGNUroGen Pharma2026-10-19 12:00 EST

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

CGEMCullinan Therapeutics, Inc.2026-10-01 23:30 EST

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

ELVNEnliven Therapeutics2026-10-06 20:05 EST

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

BMYBMYBristol-Myers Squibb Company2026-09-30 21:32 EST

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

View all latest news

Prelude Therapeutics

Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition. PRT12396 PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis. PRT13722 PRT13722 is an oral KAT6A degrader intended for...

Recent company news

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

PRLDPrelude Therapeutics2026-10-13 11:01 EST

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PRLDPrelude Therapeutics2026-09-10 11:01 EST

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

PRLDPrelude Therapeutics2026-08-11 11:00 EST

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
3.56 USD
Market cap
278.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States